Business
Rein Therapeutics Announces Closing of $57.5 Million Underwritten Public Offering, Including Full Exercise of Over-Allotment Option
Offering oversubscribed through full exercise of underwriters’ option, supported by strong investor demandTotal gross proceeds increased to $57.5 millionOffering consisted solely of common stockProceeds expected to fund Phase 2 trial of LTI-03 in IPF through completion and support operations into 2028 AUSTIN, Texas, May 18, 2026 (GLOBE NEWSWIRE) -- Rein Therapeutics, Inc. ("Rein" or the "Company") (NASDAQ: RNTX), a clinical-stage biopharmaceutical company advancing a novel pipeline of first-in-c
About this update from Rein Therapeutics, Inc.
[{"type":"image","alt":"Rein Therapeutics","displaySize":"","headline":null,"caption":"Rein Therapeutics","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":188,"url":"https://media.zenfs.com/en/globenewswire.com/f6e817856ccb7baaad5e04eaa3b79161"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/zDV0mEshpxFP_du15eFNsg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTI2Mw--/https://media.zenfs.com/en/globenewswire.com/f6e817856ccb7baaad5e04eaa3b79161","width":300,"height":188},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/zDV0mEshpxFP_du15eFNsg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTI2Mw--/https://media.zenfs.com/en/globenewswire.com/f6e817856ccb7baaad5e04eaa3b79161","width":300,"height":188}},"lazy":false},{"type":"text","content":"Offering oversubscribed through full exercise of underwriters’ option, supported by strong investor demand","length":106,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Total gross proceeds increased to $57.5 million","length":47,"tagName":"p"}]},{"val":[{"type":"text","content":"Offering consisted solely of common stock","length":41,"tagName":"p"}]},{"val":[{"type":"text","content":"Proceeds expected to fund Phase 2 trial of LTI-03 in IPF through completion and support operations into 2028","length":108,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":196,"olType":false},{"type":"text","content":"AUSTIN, Texas, May 18, 2026 (GLOBE NEWSWIRE) -- Rein Therapeutics, Inc. ("Rein" or the "Company") (NASDAQ: RNTX), a clinical-stage biopharmaceutical company advancing a novel pipeline of first-in-class medicines for orphan pulmonary and fibrosis indications, today announced the closing of its previously announced underwritten public offering of common stock, including the full exercise of the underwriters’ over-allotment option. The financing included new and existing healthcare-focused investors, including Adar1 Capital Management LLC, Ikarian Capital LLC, Bios Partners, Stonepine Capital Management, Cable Car Capital LP, and Second Line Capital.","length":675,"tagName":"p"},{"type":"text","content":"In total, 57.5 million shares were sold at $1.00 per share, resulting in aggregate gross proceeds of $57.5 million, before deducting underwriting discounts and commissions and other expenses.","length":191,"tagName":"p"},{"type":"text","content":"The tr...